Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cd38 (Adp-Ribosyl Cyclase 1, Cyclic Adp-Ribose Hydrolase 1, Cadpr Hydrolase 1, Cadpr1)], Humanized Monoclonal Antibody
Lymphoma
Explore 288 assets in Lymphoma →Floatz Rating
C37/100
Confidence
Indicative
Sponsor
Keymed Biosciences Co.Ltd
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04818372CT.gov Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cd38 (Adp-Ribosyl Cyclase 1, Cyclic Adp-Ribose Hydrolase 1, Cadpr Hydrolase 1, Cadpr1)], Humanized Monoclonal Antibody (this asset) | Keymed Biosciences Co.Ltd | P1 | C · 37 |
| Vinblastine | Intensity Therapeutics, Inc. | P4 | BBB |
| Prednisolone | The Lymphoma Academic Research Organisation | P4 | BBB |
| Etoposide | Memorial Sloan Kettering Cancer Center | P4 | BBB |
| Bleomycin | Shandong Provincial Hospital | P4 | BBB |
| Prednisone | Beth Israel Deaconess Medical Center | P4 | BBB |
| Vincristine Sulfate | Inhye Ahn | P3 | BBB |
| Cyclophosphamide | Beth Israel Deaconess Medical Center | P4 | BB |
| Methotrexate | University of Chicago | P4 | BB |
+42 more in the Lymphoma cohort
Other indications for Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cd38 (Adp-Ribosyl Cyclase 1, Cyclic Adp-Ribose Hydrolase 1, Cadpr Hydrolase 1, Cadpr1)], Humanized Monoclonal Antibody
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasma Cell Myeloma | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cd38 (Adp-Ribosyl Cyclase 1, Cyclic Adp-Ribose Hydrolase 1, Cadpr Hydrolase 1, Cadpr1)], Humanized Monoclonal Antibody in Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-kappa-anti-homo-sapiens-cd38-adp-ribosyl-cyclase-1-cyclic-adp-ribose-hydrolase-1-cadpr-hydrolase-1-cadpr1-humanized-monoclonal-antibody-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →